Exploring the impact of declining IgG4 levels post-vaccination on immunity and potential risks.
-
Dr. Philip McMillan discusses the significance of IgG4 levels in immunity post-vaccination. • 0:03
-
Antibody levels post-infection typically average around 300 nanog per mil. • 1:58
-
Concerns raised about significant rise in IgG4 levels post-vaccination. • 2:26
-
IgG4, an unusual pattern in mRNA vaccination, poses potential risks to immune response. • 4:06
Impact of IgG4 levels post-vaccination on immune response and viral replication.
-
IgG4 triggers immune system response, while IgG4 dampens it down. • 4:30
-
Significant increase in IgG4 levels post mRNA vaccination. • 6:00
-
Unexpected tolerance development towards Spike protein post-vaccination. • 6:32
-
IgG4 interferes with virus cell entry but not replication. • 7:05
-
High levels of viral dissemination observed in vaccinated cohorts. • 7:32
-
Shift towards IgG4 antibodies post mRNA vaccination. • 7:48
-
Increased IgG4 levels post-vaccination regardless of prior infection. • 8:25
Implications of low IgG4 levels in viral infections and vaccine response.
-
Low levels of IgG4 in viral infections may lead to viral dissemination. • 9:27
-
High levels of IgG4 may interfere with viral replication. • 9:47
-
Tolerant antibodies suppressing the immune system raises concerns when they fall. • 10:14
-
Risk-benefit analysis needed for vaccine interventions. • 10:41
-
Importance of understanding disease presentation and vaccine uptake. • 11:11
-
Data on antibody levels can provide insights into immunity trajectories. • 11:48
-
Minimum IgG4 levels in normal infection compared to observed levels. • 12:05
Concerns regarding declining IgG4 levels and potential hyperimmune response.
-
Antibody levels above 800 nanograms per mill considered protective. • 12:47
-
Up to 93% in age group under 65 and 98% in over 65s had protective antibody levels. • 12:54
-
Low vaccine booster uptake despite high antibody levels in certain age groups. • 13:33
-
30-40% of age group 16-24 have antibody levels between 179 to 800 nanograms per mill. • 14:04
-
Concerns raised about majority having antibody levels above 6,000 in older age groups. • 15:30
-
Shift from IgG4 to cellular response when levels fall may lead to hyperimmune response. • 16:52
-
Potential risk of hyperimmune response due to lack of IgG4 and viral dissemination. • 17:00
Potential consequences of declining IgG4 levels and the uncertainty surrounding further antibody boosting.
-
Concerns about immune response targeting various organs beyond the lung. • 17:43
-
Uncertainty on the effectiveness of further antibody boostin. • 18:17
-
Lack of clarity on managing potential inflammatory response. • 19:01
-
Suggestion to consider alternative immune-suppressing treatment. • 19:25
-
Critique of leadership’s handling of public health challenge. • 19:47
-
Call for scientific preparation and readiness for potential adverse outcome. • 20:03
-
Encouragement to stay informed and proactiv. • 20:12